Research programme: angiogenesis inhibitors - Medexis

Drug Profile

Research programme: angiogenesis inhibitors - Medexis

Alternative Names: Angiomed Project; MED-A300; MED-A301

Latest Information Update: 10 Dec 2010

Price : $50

At a glance

  • Originator Medexis
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Sep 2004 Compounds from this research programme are available for licensing (http://www.medexis-biotech.com)
  • 06 Aug 2004 Preclinical trials in Cancer in Greece (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top